The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Sermorelin vs CJC-1295 vs Tesamorelin

Three-way comparison of GHRH analogues: Sermorelin, CJC-1295, and Tesamorelin — half-lives, GH pulse patterns, IGF-1 elevation, and appropriate research applications.

Half-Life Comparison

Sermorelin: ~10–20 min (pulsatile). CJC-1295 no DAC: ~30 min (pulsatile). CJC-1295 with DAC: 6–8 days (sustained). Tesamorelin: ~26 min (pulsatile, more sustained than sermorelin). The half-life determines whether GH release is pulsatile or continuous.

IGF-1 Elevation Comparison

Sermorelin: modest elevation, requires multiple daily injections. CJC-1295 with DAC: 200–400% above baseline with weekly dosing. Tesamorelin: 100–150 ng/mL above baseline with once-daily dosing. CJC-1295 DAC produces the highest IGF-1 elevation.

Choosing the Right Analogue

Sermorelin: lowest cost, physiological pulsatility. CJC-1295 no DAC: combine with GHRP for synergistic GH release. CJC-1295 with DAC: maximum IGF-1 elevation, weekly dosing. Tesamorelin: highest clinical evidence, FDA-validated.